Sacubitril-valsartan for heart shape and pumping in congenital heart disease
Tests sacubitril-valsartan against placebo in adults with congenital heart disease.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- Effect of Sacubitril-Valsartan on Cardiac Structure and Function
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 45 people, planned
- Started
- 3 Feb 2025
- Expected to end
- Aug 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Entresto Pill
- Placebo
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with congenital heart disease, meaning a heart problem present from birth. Participants get Entresto (sacubitril-valsartan) or a placebo (dummy pill).
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- A diagnosis of congenital heart disease
- Earlier treatment
- People cannot join if they currently take an ACE inhibitor, ARB or ARNI. Other listed drugs also rule people out: Amifostine, Droperidol, Dantrolene, CYP3A4 Inhibitors, Obinutuzumab, Aliskiren, Lithium, Sparsentan.
Main reasons for not taking part
- Stage IV chronic kidney disease (creatinine clearance <30 ml/min)
- High blood potassium (serum potassium >5.2 mmol/l)
- Low blood pressure (systolic blood pressure <100 mmHg)
- Past swelling (angioedema) from ACE or ARB drugs
- Pregnancy, or diabetes treated with Aliskiren
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Congenital Heart Disease Diagnosis
- Age 18 or Older
Who cannot take part
- History of angioedema related to previous ACE or ARB therapy
- Drug Therapies; Amifostine; Droperidol; Dantrolene; CYP3A4 Inhibitors; Obinutuzumab; Aliskiren; Lithium; Sparsentan; ACE inhibitor; ARB; ARNI
- Patients diagnosed with diabetes using Aliskiren,
- Stage IV chronic kidney disease defined as creatinine clearance <30 ml/min
- Hyperkalemia defined as serum potassium >5.2 mmol/l,
- Hypotension defined as systolic blood pressure <100 mmHg,
- Pregnancy
Where in United States
- Mayo Clinic in RochesterRochester, United StatesContact: Amanda WozniakTaking people
About the trial
What the trial wants to find out
The purpose of this study is to compare changes in cardiac structure and function, biomarkers, and patient reported outcomes between adults with congenital heart disease (ACHD) randomized to angiotensin receptor-neprilysin inhibitor (ARNI) therapy vs placebo.
The 2 groups in the trial
- EntrestoTreatment being tested
Treatment: Entresto Pill
- PlaceboPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Effect of Sacubitril-Valsartan on Cardiac Structure and Function in Adults With Congenital Heart Disease
- Plain-language title
- Sacubitril-valsartan for heart shape and pumping in congenital heart diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 9 October 2026